Jill Woodworth

Episode 3 of TSC Talks 3.0 ResearchI drill down with the AI on the reality of what is happening in the rare disease expanse. The full expanse it's not explored we are jumping right into gene editing, like using whiteout, it isn't quite the same. It's a closed loop system. That is for sure. links:https://www.ninds.nih.gov/health-information/disorders/tuberous-sclerosis-complex#https://pmc.ncbi.nlm.nih.gov/articles/PMC7672342/https://www.ncbi.nlm.nih.gov/books/NBK1220/#https://patienteducation.asgct.org/understanding-cell-gene-therapy/ethical-issues-germline-gene-editing# https://pmc.ncbi.nlm.nih.gov/articles/PMC12103018/# https://pubmed.ncbi.nlm.nih.gov/6873497/#https://pmc.ncbi.nlm.nih.gov/articles/PMC6277505/# https://www.researchgate.net/publication/326455213_Incidence_of_tuberous_sclerosis_and_age_at_first_diagnosis_new_data_and_emerging_trends_from_a_national_prospective_surveillance_studyhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11944049/# https://www.slu.edu/law/health/blog/2024/vence-bonham-dss.php#http